Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Core Insights - Adial Pharmaceuticals has completed patient dosing for the second cohort in the pharmacokinetics study of AD04, with topline results expected in Q4 2024 [1][2] - The completion of dosing is a significant milestone towards initiating a Phase 3 clinical trial aimed at optimizing dosing for AD04 in patients with Alcohol Use Disorder (AUD) [2] - The study involved 30 healthy adult volunteers and compared the pharmacokinetic profile of AD04 at a dose of 0.33 mg, with or without food, against a reference standard product [2] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders [3] - The lead investigational product, AD04, is a genetically targeted serotonin-3 receptor antagonist for treating AUD in heavy drinking patients [3] - AD04 has shown promising results in reducing drinking in heavy drinking patients during the ONWARD™ pivotal Phase 3 clinical trial, with no significant safety or tolerability concerns [3] - The company believes AD04 may also have potential applications in treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [3]